DaShenLin Pharmaceutical Group Co Ltd banner
D

DaShenLin Pharmaceutical Group Co Ltd
SSE:603233

Watchlist Manager
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Watchlist
Price: 17.98 CNY 1.07%
Market Cap: ¥20.5B

EV/OCF

4.3
Current
33%
Cheaper
vs 3-y average of 6.4

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
4.3
=
Enterprise Value
¥20.4B
/
Operating Cash Flow
¥4.3B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
4.3
=
Enterprise Value
¥20.4B
/
Operating Cash Flow
¥4.3B

Valuation Scenarios

DaShenLin Pharmaceutical Group Co Ltd is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (6.4), the stock would be worth ¥26.73 (49% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+382%
Average Upside
217%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 4.3 ¥17.98
0%
3-Year Average 6.4 ¥26.73
+49%
5-Year Average 10.4 ¥43.2
+140%
Industry Average 17.1 ¥71.16
+296%
Country Average 20.8 ¥86.72
+382%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close

Market Distribution

Lower than 91% of companies in China
Percentile
9th
Based on 6 190 companies
9th percentile
4.3
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

DaShenLin Pharmaceutical Group Co Ltd
Glance View

Market Cap
20.5B CNY
Industry
Retail

DaShenLin Pharmaceutical Group Co., Ltd. is a fascinating entity woven into the intricate fabric of China's rapidly evolving healthcare landscape. Stemming from humble origins, the company has blossomed into a significant player in the pharmaceutical industry. DaShenLin's business model adeptly combines the traditional with the modern, strategically positioning itself across the supply and distribution spectrum. Primarily, it operates through an extensive retail network, boasting a formidable chain of pharmacies thoughtfully dotted across various provinces. These pharmacies are more than mere outlets; they serve as community health sanctuaries offering an array of pharmaceutical products and health consultations. The company's commitment to traditional Chinese medicine sets it apart, further establishing a niche by fusing age-old healing practices with contemporary medicinal needs. The company's revenue streams are as diverse as its product offerings. Predominantly, it derives income from the direct sale of pharmaceuticals, encompassing both Western drugs and traditional Chinese medicines. Additionally, DaShenLin capitalizes on its robust wholesale operations, providing a steady pipeline of medicinal products to regional hospitals and clinics. The company thrives on its comprehensive supply chain, which ensures an uninterrupted flow of goods from production to consumers' hands. With a keen emphasis on quality and efficacy, DaShenLin continuously invests in research and development, fostering innovation within its product lines. This strategic focus not only reinforces consumer trust but also secures its competitive edge within a dynamic market landscape.

Intrinsic Value
27.05 CNY
Undervaluation 34%
Intrinsic Value
Price ¥17.98
D
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett